3 stories mentioning HKG:2487Updated 1d ago
Every FINWIRES story that references HKG:2487, newest first.
Cutia Therapeutics (HKG:2487) said its CU-40102 topical finasteride spray received marketing approval from Macao's Pharmaceutical Administration Bureau for the treatment of androgenetic alopecia, according to a Monday Hong Kong bourse filing.The approval follows marketing authorizations from China's National Medical Products Administration and Hong Kong's Department of Health.
Cutia Therapeutics' (HKG:2487) topical anesthetic CU-30101 was approved in China, the firm said in a Hong Kong bourse filing Thursday.The medicine, a formulation of lidocaine and tetracaine cream, was approved based on the results of its phase 3 clinical trial, which showed the product worked as well as the reference drug Pliaglis.
Cutia Therapeutics (HKG:2487) said it completed a Phase 3 clinical trial in China for its botulinum toxin type A product for treating moderate to severe glabellar lines, according to a Monday Hong Kong bourse filing.The study met primary and secondary endpoints, with efficacy comparable to Botox and a favorable safety profile.The pharmaceutical company said no treatment-related serious adverse events or new safety signals were observed.
